HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Neurogene (NASDAQ:NGNE) and maintained a $45 price target.
March 05, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Neurogene with a $45 price target.
The reiteration of a Buy rating and maintenance of a $45 price target by a reputable analyst could positively influence investor sentiment towards NGNE, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100